• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

新型食品评估流程延缓了欧盟食品创新的推广。

The novel food evaluation process delays access to food innovation in the European Union.

作者信息

Le Bloch Jérôme, Rouault Marie, Langhi Cédric, Hignard Malorie, Iriantsoa Victoria, Michelet Olivier

机构信息

FoodChain ID, 6 rue de la gare, 22000, Saint-Brieuc, France.

出版信息

NPJ Sci Food. 2025 Jul 1;9(1):117. doi: 10.1038/s41538-025-00492-x.

DOI:10.1038/s41538-025-00492-x
PMID:40593922
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12219162/
Abstract

This article analyzes the timelines of 292 novel food (NF) applications submitted to EFSA between 2018 and 2024 under Regulation (EU) 2015/2283. The average duration from submission to publication was 2.56 ± 1.19 years, with significant variability, and delays due to suitability checks and additional data requests. Improved guidelines and pre-submission support could streamline the process, fostering innovation and timely market access for NFs.

摘要

本文分析了2018年至2024年期间根据（欧盟）2015/2283号法规提交给欧洲食品安全局（EFSA）的292份新型食品（NF）申请的时间线。从提交到发布的平均时长为2.56±1.19年，存在显著差异，且因适用性检查和额外数据要求而出现延迟。改进指南和提交前支持可以简化流程，促进新型食品的创新和及时进入市场。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4603/12219162/a985dd041d0e/41538_2025_492_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4603/12219162/beb05efed7d0/41538_2025_492_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4603/12219162/364571eb5b1f/41538_2025_492_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4603/12219162/a985dd041d0e/41538_2025_492_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4603/12219162/beb05efed7d0/41538_2025_492_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4603/12219162/364571eb5b1f/41538_2025_492_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4603/12219162/a985dd041d0e/41538_2025_492_Fig3_HTML.jpg

相似文献

1
The novel food evaluation process delays access to food innovation in the European Union.新型食品评估流程延缓了欧盟食品创新的推广。
NPJ Sci Food. 2025 Jul 1;9(1):117. doi: 10.1038/s41538-025-00492-x.
2
Does Augmenting Irradiated Autografts With Free Vascularized Fibula Graft in Patients With Bone Loss From a Malignant Tumor Achieve Union, Function, and Complication Rate Comparably to Patients Without Bone Loss and Augmentation When Reconstructing Intercalary Resections in the Lower Extremity?对于因恶性肿瘤导致骨缺损的患者，在重建下肢节段性切除时，采用带血管游离腓骨移植来增强照射后的自体骨移植，其骨愈合、功能及并发症发生率与无骨缺损且未进行增强的患者相比是否相当？
Clin Orthop Relat Res. 2025 Jun 26. doi: 10.1097/CORR.0000000000003599.
3
Assessment of whether use of a professional medical writer is associated with time to publication of papers reporting phase III oncology clinical trials in two high-impact general medicine journals.评估在两家高影响力的普通医学期刊上，使用专业医学撰写人员是否与报告肿瘤学III期临床试验的论文发表时间相关。
Curr Med Res Opin. 2025 May;41(5):887-893. doi: 10.1080/03007995.2025.2505697. Epub 2025 May 23.
4
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.用于预防和治疗健康成人及儿童流感的神经氨酸酶抑制剂。
Cochrane Database Syst Rev. 2012 Jan 18;1:CD008965. doi: 10.1002/14651858.CD008965.pub3.
5
Direct-acting antivirals for chronic hepatitis C.用于慢性丙型肝炎的直接作用抗病毒药物。
Cochrane Database Syst Rev. 2017 Sep 18;9(9):CD012143. doi: 10.1002/14651858.CD012143.pub3.
6
Ultrasound and shockwave therapy for acute fractures in adults.成人急性骨折的超声与冲击波治疗
Cochrane Database Syst Rev. 2012 Feb 15(2):CD008579. doi: 10.1002/14651858.CD008579.pub2.
7
Early additional food and fluids for healthy breastfed full-term infants.健康足月母乳喂养婴儿的早期额外食物和液体
Cochrane Database Syst Rev. 2016 Aug 30;2016(8):CD006462. doi: 10.1002/14651858.CD006462.pub4.
8
Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review.用于预防慢性骨髓衰竭所致血小板减少症患者出血的预防性血小板输注替代药物：一项荟萃分析和系统评价
Cochrane Database Syst Rev. 2016 Oct 31;10(10):CD012055. doi: 10.1002/14651858.CD012055.pub2.
9
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.
10
Inhaled mannitol for cystic fibrosis.吸入用甘露醇治疗囊性纤维化。
Cochrane Database Syst Rev. 2018 Feb 9;2(2):CD008649. doi: 10.1002/14651858.CD008649.pub3.

引用本文的文献

1
Genesis, Health Benefits, and Future Perspectives of Probiotics: Exploring Endogenous and Exogenous Classes, Innovations, and Research Gaps.益生菌的起源、健康益处及未来展望：探索内源性和外源性类别、创新与研究空白
Probiotics Antimicrob Proteins. 2025 Sep 10. doi: 10.1007/s12602-025-10756-3.

本文引用的文献

1
Polyphenols in Human Nutrition: European Regulations and Potential Classification as a Novel Food or Food Additive.人类营养中的多酚类物质：欧洲法规以及作为新型食品或食品添加剂的潜在分类
J Agric Food Chem. 2024 Dec 4;72(48):26936-26942. doi: 10.1021/acs.jafc.4c08435. Epub 2024 Nov 21.
2
Guidance on the scientific requirements for an application for authorisation of a novel food in the context of Regulation (EU) 2015/2283.关于根据欧盟法规（EU）2015/2283申请新型食品授权的科学要求指南。
EFSA J. 2024 Sep 30;22(9):e8961. doi: 10.2903/j.efsa.2024.8961. eCollection 2024 Sep.
3
Novel foods, food enzymes, and food additives derived from food by-products of plant or animal origin: principles and overview of the EFSA safety assessment.
源自植物或动物源性食品副产品的新型食品、食品酶和食品添加剂：欧洲食品安全局安全性评估的原则与概述
Front Nutr. 2024 May 3;11:1390734. doi: 10.3389/fnut.2024.1390734. eCollection 2024.
4
Current status of the novel food ingredient safety evaluation system.新型食品成分安全评估体系的现状
Food Sci Biotechnol. 2023 Aug 9;33(1):1-11. doi: 10.1007/s10068-023-01396-w. eCollection 2024 Jan.
5
Incorporation of novel foods in European diets can reduce global warming potential, water use and land use by over 80.在欧洲饮食中加入新型食品，可使全球变暖潜能、水的使用和土地利用减少 80%以上。
Nat Food. 2022 Apr;3(4):286-293. doi: 10.1038/s43016-022-00489-9. Epub 2022 Apr 25.
6
Alternative Protein Sources and Novel Foods: Benefits, Food Applications and Safety Issues.替代蛋白质来源与新型食品：益处、食品应用及安全问题。
Nutrients. 2023 Mar 21;15(6):1509. doi: 10.3390/nu15061509.
7
Guidance on the preparation and submission of an application for authorisation of a novel food in the context of Regulation (EU) 2015/2283 (Revision 1).关于根据（欧盟）2015/2283号法规（修订版1）准备和提交新型食品授权申请的指南。
EFSA J. 2021 Mar 26;19(3):e06555. doi: 10.2903/j.efsa.2021.6555. eCollection 2021 Mar.
8
Novel foods in the European Union: Scientific requirements and challenges of the risk assessment process by the European Food Safety Authority.欧盟的新型食品：欧洲食品安全局风险评估过程的科学要求与挑战
Food Res Int. 2020 Nov;137:109515. doi: 10.1016/j.foodres.2020.109515. Epub 2020 Jul 7.
9
European Regulatory Framework and Safety Assessment of Food-Related Bioactive Compounds.欧洲食品相关生物活性化合物的监管框架与安全评估。
Nutrients. 2020 Feb 26;12(3):613. doi: 10.3390/nu12030613.
10
Review of the regulation and safety assessment of food substances in various countries and jurisdictions.各国和各司法管辖区食品物质的监管和安全评估综述。
Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2013;30(7):1147-220. doi: 10.1080/19440049.2013.795293. Epub 2013 Jun 20.